Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-CD19 cCAR in R/R Multiple Myeloma and Plasmacytoid Lymphoma
NCT04162353Phase 1Recruiting
- Sponsor
- iCell Gene Therapeutics
- Start
- Jul 2019
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA-CD19 cCAR-T in multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL), sponsored by iCell Gene Therapeutics. Primary endpoint: Number of adverse events at 28 days. Started Jul 2019; status: recruiting.
02
Drugs
BCMA-CD19 cCAR-T
03
Conditions
multiple myeloma (MM)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04162353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162353.